Nicox S.A. (LON:0RCQ)

Market Cap	28.37M +43.2%
Revenue (ttm)	14.63M +113.4%
Net Income	-2.10M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,959
Open	0.3840
Previous Close	0.38625
Day's Range	0.38375 - 0.3840
52-Week Range	0.2820 - 0.5655
Beta	0.51
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 23, 2026

About Nicox

Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. It develops solutions to preserving vision and improve eye health. The company’s lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, an investigational ophthalmic treatment based on fluticasone propionate that is in Phase 2 clinical trial fo...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 10
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RCQ

Financial Performance

In 2025, Nicox's revenue was 16.77 million, an increase of 113.41% compared to the previous year's 7.86 million. Losses were -2.41 million, -89.22% less than in 2024.

Financial numbers in EUR

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 7, 2026

Data Sources Report a data error